<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04086264</url>
  </required_header>
  <id_info>
    <org_study_id>IMGN632-0802</org_study_id>
    <nct_id>NCT04086264</nct_id>
  </id_info>
  <brief_title>IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Patients With CD123-Positive Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Patients With CD123-Positive Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunoGen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ImmunoGen, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability&#xD;
      of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination&#xD;
      with azacitidine and/or venetoclax in patients with relapsed and frontline CD123-positive&#xD;
      AML, and antileukemia activity of IMGN632 when administered as monotherapy in patients with&#xD;
      MRD+ AML after frontline treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability&#xD;
      of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination&#xD;
      with azacitidine and/or venetoclax in patients with relapsed and frontline CD123-positive&#xD;
      AML, and antileukemia activity of IMGN632 when administered as monotherapy in patients with&#xD;
      MRD+ AML after frontline treatment.&#xD;
&#xD;
      This study explores multiple IMGN632 doses in combination and monotherapy Regimens, including&#xD;
      (A) azacitidine, (B) venetoclax, (C) azacitidine+venetoclax, and (D) monotherapy in MRD+ AML.&#xD;
      For combination Regimens A-C, a Phase 1b Dose Escalation Cohort will determine the&#xD;
      recommended Phase 2 dose (RP2D) of IMGN632 in that specific combination Regimen, followed by&#xD;
      a Phase 2 Dose Expansion Cohort for each combination Regimen to further characterize the&#xD;
      safety profile and assess the antileukemia activity of the different combination Regimens.&#xD;
      Regimen D will open with a Dose Expansion Cohort using the IMGN632 monotherapy dose and&#xD;
      schedule based on safety data from the initial Phase 2 study (IMGN632-0801) and will not have&#xD;
      a Dose Escalation Phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2019</start_date>
  <completion_date type="Anticipated">June 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 16, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>approximately 7 months</time_frame>
    <description>Evaluate the safety and tolerability and identify an RP2D of IMGN632 when administered in combination with azacitidine, with venetoclax, and with azacitidine and venetoclax, in patients with relapsed or refractory CD123-positive AML through review of Treatment Emergent Adverse Events and abnormal laboratory values that result in a failure to meet the criteria for re-treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preliminary antileukeumia activity</measure>
    <time_frame>approximately 20 months</time_frame>
    <description>Assess preliminary antileukemia activity of IMGN632 when administered as a monotherapy in MRD+ Fit and MRD+ Unfit AML patient populations, and in combination with azacitidine, with venetoclax, and with azacitidine and venetoclax in patients with relapsed or untreated AML as assessed by complete response, complete remission with partial hematologic recovery, complete remission with incomplete platelet recovery, morphologic leukemia-free state, partial response, and duration of remission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal Residual Disease Levels</measure>
    <time_frame>approximately 18 months</time_frame>
    <description>Assess Minimal Residual Disease Levels using central flow cytometry-based testing</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">274</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMGN632, administered intravenously on Day 7 of a 28 day cycle at 0.015 mg/kg, 0.045 mg/kg, or 0.09 mg/kg, in combination with azacitidine, administered subcutaneously or intravenously daily at 75 mg/m2 on Days 1 to 7 of a 28 day cycle. Cycle 1 azaciditine dose in subsequent cohorts may be reduced.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMGN632, administered intravenously on Day 7 of a 21 day cycle at 0.015 mg/kg, 0.045 mg/kg, or 0.09 mg/kg, in combination with venetoclax, administered orally daily at 100 mg on Day 1, 200mg on Day 2, and 400 mg on the day 3 up to Day 21 of a 21 day cycle. Alternate schedules with reduced venetoclax administration may be explored.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMGN632, administered intravenously on Day 7 of a 28 day cycle at 0.015 mg/kg, 0.045 mg/kg, or 0.09 mg/kg, in combination with azacitidine, administered subcutaneously or intravenously daily at 35-75 mg/m2 given for Days 1 to 7 of a 28 day cycle and venetoclax, administered orally daily at 100 mg on Day 1, 200mg on Day 2, and 400 mg on Day 3 up to Day 28 of a 28 day cycle. Alternate schedules with reduced venetoclax administration or reduced azacitidine dose or administration may be explored.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMGN632, administered intravenously on Day 1 of a 21 day cycle at 0.045 mg/kg, as a monotherapy for Fit and Unfit MRD+ patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>IMGN632 in combination with azacitidine</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <other_name>Vidaza</other_name>
    <other_name>Decitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMGN632</intervention_name>
    <description>IMGN632 in combination with azacitidine</description>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <arm_group_label>Regimen D</arm_group_label>
    <other_name>CD123-targeted ADC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>IMGN632 in combination with venetoclax</description>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_label>Regimen C</arm_group_label>
    <other_name>Venclexta</other_name>
    <other_name>Venclyxto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patient Inclusion Criteria&#xD;
&#xD;
          1. Patient must be ≥ 18 years of age.&#xD;
&#xD;
          2. Patients must have confirmed diagnosis of AML (excluding acute promyelocytic leukemia)&#xD;
             based on World Health Organization classification (Arber 2016).&#xD;
&#xD;
          3. Disease characteristics and allowable prior therapy:&#xD;
&#xD;
               1. Patients must be evaluated for any available standard of care therapies and, in&#xD;
                  the opinion of the treating physician, be deemed appropriate for this&#xD;
                  experimental therapy.&#xD;
&#xD;
               2. Treatment-naïve (untreated) patients will be allowed in the Expansion Phase for&#xD;
                  Regimens A (IMGN632 + azacitidine) and C (IMGN632 + azacitidine + venetoclax). No&#xD;
                  prior treatments with HMAs for MDS are allowed. Note: Patients who are MRD+&#xD;
                  following frontline treatment are eligible for the Regimen D Cohorts D1 and D2&#xD;
                  (Expansion Phase).&#xD;
&#xD;
               3. Patients must have CD123-positive AML as confirmed by local flow cytometry (or&#xD;
                  immunohistochemistry [IHC]).&#xD;
&#xD;
               4. Patients may have received prior CD123-targeted therapies, except IMGN632, as&#xD;
                  long as CD123 remains detectable during screening.&#xD;
&#xD;
               5. Relapsed or refractory CD123-positive AML patients will be allowed to enroll in&#xD;
                  the Escalation Phase of Regimens A, B, and C (Triplet) (IMGN632 + azacitidine,&#xD;
                  venetoclax, or azacitidine + venetoclax, respectively) and relapsed&#xD;
                  CD123-positive AML patients will be allowed to enroll the Expansion Phase of&#xD;
                  Regimens A-C.&#xD;
&#xD;
               6. Patients enrolling in Regimen D must be in CR (CR/CRi) for no more than 6 months&#xD;
                  and be MRD+, confirmed by central laboratory testing, after intensive&#xD;
                  induction/consolidation therapy. Note: Fit patients who previously received&#xD;
                  intensive treatment (eg 3+7, HiDAC, etc.) are eligible for Regimen D Cohort D1.&#xD;
                  Unfit patients who previously received non-intensive treatment (eg, HMA, low dose&#xD;
                  cytarabine, etc.) are eligible for Regimen D Cohort D2.&#xD;
&#xD;
          4. Patients enrolling on Regimen D (MRD+ AML), must first have an evaluable screening&#xD;
             bone marrow sample confirmed as MRD+ by central flow testing of MRD.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group performance status ≤ 1. If nonambulatory due to a&#xD;
             chronic disability, must be Karnofsky performance status &gt; 70.&#xD;
&#xD;
          6. Previous treatment-related toxicities must have resolved to Grade 1 or baseline&#xD;
             (excluding alopecia).&#xD;
&#xD;
          7. Total white blood cell count must be less than 25 x 10^9 cells/L. Hydroxyurea may be&#xD;
             used to control blood counts before Cycle 1 Day 1, at the discretion of the treating&#xD;
             physician, according to institutional practice. During the Escalation Phase in&#xD;
             Regimens A-C, hydroxyurea may also be used during Cycle 1.&#xD;
&#xD;
          8. Liver enzymes (AST and ALT) ≤ 3 × the upper limit of normal (ULN).&#xD;
&#xD;
          9. Total bilirubin ≤ 1.5 × the ULN within 14 days of enrollment.&#xD;
&#xD;
         10. Serum creatinine ≤ 1.5 mg/dL within 14 days of enrollment.&#xD;
&#xD;
         11. Echocardiogram or other modality demonstrating an ejection fraction ≥ 45%.&#xD;
&#xD;
         12. Patients with prior autologous and allogeneic bone marrow transplant are eligible.&#xD;
             Patients with an allogeneic transplant must meet the following conditions: The&#xD;
             transplant must have been performed more than 120 days before the date of dosing on&#xD;
             this study, the patient must not have active ≥ Grade 2 graft versus host disease, and&#xD;
             the patient must be off all systemic immunosuppression for at least 2 weeks before&#xD;
             dosing.&#xD;
&#xD;
         13. Voluntary written informed consent before performance of any study-related procedure&#xD;
             not part of normal medical care.&#xD;
&#xD;
         14. Women of childbearing potential (WCBP), defined as sexually mature women who have not&#xD;
             undergone surgical sterilization or who have not been naturally postmenopausal for at&#xD;
             least 12 consecutive months (ie, who have had menses any time in the preceding 12&#xD;
             consecutive months), must agree to use highly effective contraceptive methods&#xD;
             (examples include oral, parenteral, or implantable hormonal contraceptive,&#xD;
             intrauterine device, barrier contraceptive with spermicide, partner's latex condom or&#xD;
             vasectomy) while on study drug and for at least 7 months after the last dose of study&#xD;
             drug.&#xD;
&#xD;
         15. WCBP must have a negative pregnancy test within 3 days before the first dose of study&#xD;
             drug.&#xD;
&#xD;
         16. A male patient must agree to use a latex condom even if he has had a successful&#xD;
             vasectomy and must continue to follow these requirements for at least 12 weeks after&#xD;
             the last dose of study drug.&#xD;
&#xD;
         17. Patients with prior malignancy are eligible; however, the patient must be in remission&#xD;
             from the prior malignancy and have completed all chemotherapy and radiotherapy for the&#xD;
             prior malignancy at least 6 months before enrollment, and all treatment-related&#xD;
             toxicities must have resolved to Grade 1 or less.&#xD;
&#xD;
        Patient Exclusion Criteria&#xD;
&#xD;
          1. Patients who have received any anticancer therapy, including investigational agents,&#xD;
             within 14 days (or within 28 days for checkpoint inhibitors) before drug&#xD;
             administration on this study (hydroxyurea is allowed before beginning study&#xD;
             treatment). Patients must have recovered to baseline from all acute toxicity from this&#xD;
             prior therapy.&#xD;
&#xD;
          2. Patients who have been previously treated with IMGN632.&#xD;
&#xD;
          3. Patients with myeloproliferative neoplasm-related secondary AML are excluded from the&#xD;
             Dose Expansion Phase of the study.&#xD;
&#xD;
          4. Patients with active central nervous system (CNS) AML will be excluded. A lumbar&#xD;
             puncture does not need to be performed unless there is clinical suspicion of CNS&#xD;
             involvement per investigator judgement. Concurrent therapy for CNS prophylaxis or&#xD;
             continuation of therapy for controlled CNS AML is allowed with the approval of the&#xD;
             sponsor.&#xD;
&#xD;
          5. Patients with a history of sinusoidal obstruction syndrome/venous occlusive disease of&#xD;
             the liver.&#xD;
&#xD;
          6. Myocardial infarction within 6 months before enrollment or New York Heart Association&#xD;
             Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular&#xD;
             arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction&#xD;
             system abnormalities before study entry.&#xD;
&#xD;
          7. Clinically relevant active infection including known active hepatitis B or C, HIV&#xD;
             infection, or cytomegalovirus or any other known concurrent infectious disease that,&#xD;
             in the judgment of the investigator, would make a patient inappropriate for enrollment&#xD;
             into this study (testing not required).&#xD;
&#xD;
          8. Patients who have undergone a major surgery within 4 weeks (or longer if not fully&#xD;
             recovered) before study enrollment.&#xD;
&#xD;
          9. Serious or poorly controlled medical conditions that could be exacerbated by treatment&#xD;
             or that would seriously compromise safety assessment or compliance with the protocol,&#xD;
             in the judgment of the investigator.&#xD;
&#xD;
         10. Women who are pregnant or breastfeeding.&#xD;
&#xD;
         11. Prior known hypersensitivity reactions to monoclonal antibodies (≥ Grade 3).&#xD;
&#xD;
         12. Prior known hypersensitivity reactions to study drugs and/or any of their excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Zweidler-McKay, MD</last_name>
    <role>Study Director</role>
    <affiliation>ImmunoGen, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ImmunoGen Clinical Trials</last_name>
    <phone>781-895-0600</phone>
    <email>medicalaffairs@immunogen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Aribi, MD</last_name>
      <phone>626-218-1133</phone>
      <email>aaribi@coh.org</email>
    </contact>
    <contact_backup>
      <phone>877-467-3411</phone>
    </contact_backup>
    <investigator>
      <last_name>Ahmed Aribi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica de Santiago</last_name>
      <phone>1-877-UC -STUDY</phone>
      <email>ucstudy@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Deepa Jeyakumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsea Pershing</last_name>
      <phone>813-745-4075</phone>
      <email>Chelsea.Pershing@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Kendra Sweet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Tran</last_name>
      <phone>312-695-0503</phone>
      <email>tony.tran1@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Jessica Altman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lourdes Mendez, MD</last_name>
      <phone>617-667-9932</phone>
      <email>lmendez@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Lourdes Mendez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Geisler</last_name>
      <email>MargaretB_Geisler@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel DeAngelo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Halliwell</last_name>
      <phone>716-845-4971</phone>
    </contact>
    <contact_backup>
      <email>Stephanie.Halliwell@roswellpark.org</email>
    </contact_backup>
    <investigator>
      <last_name>Eunice Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NewYork-Presbyterian - Weill Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tania J Curcio</last_name>
      <phone>212-746-2571</phone>
      <email>tjc9003@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Gail Roboz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Stowe</last_name>
      <phone>919-681-4769</phone>
      <email>rachel.stowe@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Harry Erba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corrine Braynard</last_name>
      <phone>216-445-1019</phone>
      <email>braynac@cccf.org</email>
    </contact>
    <investigator>
      <last_name>Anjali Advani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joie Alvarez</last_name>
      <phone>713-792-7321</phone>
      <email>JAlvarez1@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Naval Daver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cherise Athay</last_name>
      <phone>206-667-4536</phone>
      <email>cathay@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Roland Walter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anasthasia Gama</last_name>
      <phone>+ 33 (0) 4 92 03 10 35</phone>
      <email>anasthasia.gama@nice.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Lauris Gastaud, MD</last_name>
      <phone>+ 33 (0) 492031221</phone>
      <email>Lauris.GASTAUD@nice.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Lauris Gastaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karolin Hubert</last_name>
      <phone>+49 341 97-20363</phone>
      <email>karolin.hubert@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Jana Heinrichs-Knopf</last_name>
      <phone>+49 341 97 12634</phone>
    </contact_backup>
    <investigator>
      <last_name>Uwe Platzbecker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabine Kayser, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ayten Sagir</last_name>
      <phone>0731-45927</phone>
      <email>ayten.sagir@uniklinik-ulm.de</email>
    </contact>
    <contact_backup>
      <last_name>Tobias Glöggler</last_name>
      <phone>0731-45746</phone>
      <email>tobias.gloeggler@uniklinik-ulm.de</email>
    </contact_backup>
    <investigator>
      <last_name>Silke Kapp-Schwoerer, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank Rueker, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia &quot;Lorenzo e A. Seragnoli&quot; - Policlinco S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Curti, MD</last_name>
      <phone>+390512144074</phone>
      <email>antonio.curti@unibo.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Curti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federica Frabetti</last_name>
      <phone>0039 0543 739292</phone>
      <email>federica.frabetti@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Martinelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Maggiore Della Carita Novara</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Gaidano, MD</last_name>
      <email>gianluca.gaidano@med.unipo.it</email>
    </contact>
    <investigator>
      <last_name>Gianluca Gaidano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Madrid, Spain</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adolfo de La Fuente, MD</last_name>
      <phone>+34917878600</phone>
      <phone_ext>2883</phone_ext>
      <email>afuente@mdanderson.es</email>
    </contact>
    <investigator>
      <last_name>Adolfo de La Fuente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico de La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Pellicer</last_name>
      <phone>0034961244864</phone>
      <email>pellicer_dav@gva.es</email>
    </contact>
    <investigator>
      <last_name>Pau Montesinos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>September 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Minimal detectable disease</keyword>
  <keyword>MRD</keyword>
  <keyword>CD123</keyword>
  <keyword>Relapsed/refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

